Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes
Get Live Data
22.50    1.00 (4.65%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £31.18m
SAR Live PriceLast checked at - London Stock Exchange

Intraday Sareum Share Chart

Corporate update

19 Jun 2008 07:00

RNS Number : 0476X
Sareum Holdings PLC
19 June 2008
 



19 June 2008

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Corporate Update

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, announced on 2 May 2008, that the Board was undertaking a strategic review to consider how best to take the business forward and create value for shareholders. 

 

On 14 May, the Company announced that as part of the strategic review, the board had implemented a staff restructuring process to reduce its cost base by approximately one third and prepare itself for any potential acquisition or re-financing whilst the future business strategy is under consideration. The restructuring programme has been successfully completed and the Sareum board will continue to review the Company's cost base diligently. In addition, the Company is making progress on a number of fronts and these are described below.

Following announcement of the review on 2 May, Sareum has received expressions of interest in parts or all of its business, particularly its valuable drug discovery programmes, and has received interest in and possible offers to partner, fund, acquire or invest in certain of its programmes or assets. Any transaction resulting from these discussions would lead to an injection of cash into the Company. Initial due diligence is currently being undertaken in respect of several of these discussions. These discussions are at various stages and there is no certainty that any one of them will lead to an offer being made for the Company or any of its assets. The Sareum board continues to actively progress discussions and further announcements will be made as appropriate. 

The Board has concluded, as a result of this review, that the Company should undertake a strategic transaction and it will need to effect a fundraising to enable it to complete such a transaction. In order to facilitate this, the Company will shortly be sending a notice to shareholders convening a general meeting at which shareholders will be asked to give the directors authority to issue further shares for cash. Should the Board decide within a short timescale that strategic transaction is not achievable, the Board will take a decision as to the future of the Company in its present form, as the Company would not be able to continue operations without a significant fundraising.

- Ends-

For further information please contact

Sareum Holdings plc

01223 497700

Tim Mitchell, Chief Executive Officer

 

Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson 

 

Grant Thornton Corporate Finance

020 7383 5100

Philip Secrett, Colin Aaronson

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQVLFFVQBZBBD
Date   Source Headline
1st May 20267:00 amRNSExercise of Warrants
12th Mar 20267:00 amRNSHalf-Year Report for Six Months Ended 31 Dec 2025
12th Mar 20267:00 amRNSHalf-Year Report for Six Months Ended 31 Dec 2025
3rd Mar 20267:00 amRNSNotice of Results and Investor Presentation
17th Feb 20267:00 amRNSRestart of Phase 2-enabling toxicology programme
23rd Jan 20264:36 pmRNSForm 8.3 - Oxford Biomedica plc
9th Dec 20254:25 pmRNSResults of AGM
9th Dec 20257:00 amRNSAnnual General Meeting Statement
17th Nov 20257:00 amRNSNotice of AGM, Annual Report and Accounts
30th Oct 20257:00 amRNSAppointment of Joint Corporate Broker
23rd Oct 20257:00 amRNSPreliminary Results for Year Ended 30 June 2025
10th Oct 20257:00 amRNSUpdate on toxicology study for SDC-1801
7th Oct 20257:00 amRNSNotice of Results and Investor Presentation
26th Sep 20253:12 pmRNSExercise of Warrants
18th Sep 202512:59 pmRNSExercise of Warrants
26th Aug 20257:00 amRNSExercise of Warrants
20th Aug 202510:01 amRNSExercise of Warrants
12th Aug 20257:00 amRNSSareum Collaboration with Receptor.AI
9th Jul 20257:00 amRNSExercise of Warrants
4th Jul 20257:00 amRNSAppointment of Sole Broker
29th May 20257:00 amRNSInitiation of Toxicology Studies for SDC-1801
28th Apr 20257:00 amRNSUpdate on TYK2/JAK1 and SRA737 Programmes
24th Apr 20257:00 amRNSExercise of Warrants
27th Mar 20257:00 amRNSDirector’s Dealing
25th Mar 20257:00 amRNSSareum Half-Year Report
20th Mar 20257:00 amRNSNotice of HY Results and Investor Presentation
13th Mar 20257:15 amRNSInstitutional Equity Fundraise
13th Mar 20257:08 amRNSSareum Acquires Licence for SRA737
31st Dec 20247:00 amRNSUpdate on SRA737
19th Dec 20244:07 pmRNSResults of AGM
19th Dec 20247:00 amRNSAGM Statement
18th Dec 20247:00 amRNSAppointment of Joint Broker
17th Dec 20249:14 amRNSHolding(s) in Company
16th Dec 20247:00 amRNSAward of Share Options
27th Nov 20249:38 amRNSNotice of AGM, Annual Report and Accounts
29th Oct 20247:00 amRNSFinal Results for the Year Ended 30 June 2024
23rd Oct 20247:00 amRNSNotice of Final Results and Investor Presentation
21st Oct 20247:00 amRNSFurther Subscription to raise £1,000,000
11th Oct 20247:00 amRNSSubscription to raise £2,364,000
16th Sep 20247:00 amRNSPatent Allowance in China
2nd Sep 20247:00 amRNSUS patent allowance
10th Jul 20247:00 amRNSManagement Changes
1st Jul 20247:00 amRNSPositive Data from SDC-1801 Phase 1 Clinical Trial
30th May 20247:00 amRNSAppointment of Sole Broker
7th May 20242:10 pmRNSExercise of Warrants
23rd Apr 20247:00 amRNSFinal Issue of RiverFort Subscription Shares
19th Apr 202411:35 amRNSIssue of RiverFort Subscription Shares
15th Apr 20243:28 pmRNSIssue of RiverFort Subscription Shares
9th Apr 20244:00 pmRNSIssue of RiverFort Subscription Shares
4th Apr 20242:38 pmRNSCompletion of Equity Fundraise

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.